Protagonist Therapeutics. has filed a patent for compositions and methods to treat sickle cell disease by administering a hepcidin mimetic or its salt. The method aims to provide effective treatment for the disease. GlobalData’s report on Protagonist Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Protagonist Therapeutics, Cyclosporin derivatives was a key innovation area identified from patents. Protagonist Therapeutics's grant share as of January 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of sickle cell disease using hepcidin mimetic
A patent application (Publication Number: US20240016895A1) discloses a method for treating sickle cell disease by administering a hepcidin mimetic or a pharmaceutical composition containing the mimetic to a subject. The hepcidin mimetic is a peptide with a specific amino acid sequence, optionally PEGylated or conjugated to a lipophilic substituent. The method involves administering the mimetic subcutaneously at doses ranging from 0.1 mg/kg to 100 mg/kg, with varying frequencies per week over the course of treatment. The subject may experience improvements in red blood cell counts, hemoglobin levels, hematocrit, and lymphocyte counts. The method targets sickle cell anemia, HbSß0 thalassemia, HbSß+ thalassemia, or hemoglobin SC disease.
The hepcidin mimetic in the method is a peptide with specific sequences or structures, administered subcutaneously at varying doses and frequencies. The treatment aims to address sickle cell disease by improving blood parameters such as red blood cell counts, hemoglobin levels, and hematocrit. The method offers potential benefits for subjects with sickle cell anemia, HbSß0 thalassemia, HbSß+ thalassemia, or hemoglobin SC disease. The patent application outlines a detailed approach involving the administration of the hepcidin mimetic to achieve therapeutic effects on the subject's blood parameters, highlighting the potential for advancements in treating sickle cell disease.
To know more about GlobalData’s detailed insights on Protagonist Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
